Journal of Herbal Medicine最新文献_第3页

Exploiting in vitro gastric acid-neutralising synergy between Desmodium triflorum (L.) DC. and Pogostemon heyneanus Benth. in an antacid tablet formulation

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-02-01 DOI: 10.1016/j.hermed.2024.100981

Bhavantha Dias , Banukie Jayasuriya , Dilanthi Herath , Menuka Arawwawala

Introduction

This study aimed to evaluate the combinative in vitro antacid activity of two terrestrial medicinal plants; Desmodium triflorum and Pogostemon heyneanus, and to subsequently formulate an antacid dosage form using their extracts.

Methods

The gastric acid-neutralising activity of crude aqueous extract combinations of D. triflorum whole plant and P. heyneanus leaves was evaluated using different in vitro assays, against distilled water. Then, the 3:1 concentration combination of D. triflorum and P. heyneanus was membrane dialysed and the resulting fractions were assayed in Vatier’s artificial stomach model. The same extract combination was characterised by high-performance liquid chromatography (HPLC) and fourier transform infrared (FTIR) analyses and then used in the formulation of herbal antacid tablets.

Results

The combination ratio of 3:1 (D. triflorum: P. heyneanus) demonstrated a significant activity (P < 0.05) in acid-neutralising effect assay (4.94 ± 0.00 end pH) and acid neutralisation duration assay (403.4 ± 4.6 seconds). The 3:1 combination further resulted in synergistic antacid activity, evidenced by the combinative index analysis. Membrane dialysed high- and low-molecular fractions of the same extract demonstrated bioactivities comparable to each other (P > 0.05) in antacid duration assay (182.78 ± 3.66 seconds and 218.18 ± 2.34 seconds respectively). The herbal tablet formulated using the 3:1 combination of the test plants showed pharmaceutically acceptable physical characteristics along with a significant acid-neutralisation (P < 0.05).

Conclusions

The 3:1 concentration combination of D. triflorum and P. heyneanus extracts resulted in synergistic gastric acid-neutralising effects, possibly with the aid of phytochemicals with various molecular weights. The combination can be further used in an antacid tablet formulation with sufficient in vitro activity.

{"title":"Exploiting in vitro gastric acid-neutralising synergy between Desmodium triflorum (L.) DC. and Pogostemon heyneanus Benth. in an antacid tablet formulation","authors":"Bhavantha Dias , Banukie Jayasuriya , Dilanthi Herath , Menuka Arawwawala","doi":"10.1016/j.hermed.2024.100981","DOIUrl":"10.1016/j.hermed.2024.100981","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to evaluate the combinative <em>in vitro</em> antacid activity of two terrestrial medicinal plants; <em>Desmodium triflorum</em> and <em>Pogostemon heyneanus</em>, and to subsequently formulate an antacid dosage form using their extracts.</div></div><div><h3>Methods</h3><div>The gastric acid-neutralising activity of crude aqueous extract combinations of <em>D. triflorum</em> whole plant and <em>P. heyneanus</em> leaves was evaluated using different <em>in vitro</em> assays, against distilled water. Then, the 3:1 concentration combination of <em>D. triflorum</em> and <em>P. heyneanus</em> was membrane dialysed and the resulting fractions were assayed in Vatier’s artificial stomach model. The same extract combination was characterised by high-performance liquid chromatography (HPLC) and fourier transform infrared (FTIR) analyses and then used in the formulation of herbal antacid tablets.</div></div><div><h3>Results</h3><div>The combination ratio of 3:1 (<em>D. triflorum</em>: <em>P. heyneanus</em>) demonstrated a significant activity (<em>P</em> < 0.05) in acid-neutralising effect assay (4.94 ± 0.00 end pH) and acid neutralisation duration assay (403.4 ± 4.6 seconds). The 3:1 combination further resulted in synergistic antacid activity, evidenced by the combinative index analysis. Membrane dialysed high- and low-molecular fractions of the same extract demonstrated bioactivities comparable to each other (<em>P</em> > 0.05) in antacid duration assay (182.78 ± 3.66 seconds and 218.18 ± 2.34 seconds respectively). The herbal tablet formulated using the 3:1 combination of the test plants showed pharmaceutically acceptable physical characteristics along with a significant acid-neutralisation (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>The 3:1 concentration combination of <em>D. triflorum</em> and <em>P. heyneanus</em> extracts resulted in synergistic gastric acid-neutralising effects, possibly with the aid of phytochemicals with various molecular weights. The combination can be further used in an antacid tablet formulation with sufficient <em>in vitro</em> activity.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"49 ","pages":"Article 100981"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adverse effects of herbal preparations of Pistacia species: a systematic review and meta-analysis of randomised controlled clinical trials

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-02-01 DOI: 10.1016/j.hermed.2024.100988

Saeid Mohseni , Narjes Gorji , Reihaneh Moeini , Zahra Meamariani , Hoda Shirafkan

Introduction

Pistacia species (spp.) have nutritional and therapeutic usage. This systematic review and meta-analysis aimed to assess the safety of herbal preparations of Pistacia spp. in the randomised controlled clinical trials.

Methods

Relevant keywords were searched in PubMed, Embase, Scopus, Web of Science, and Google Scholar up to August 2023. The quality and risk of bias were assessed using the Cochrane Collaboration tool. Pooled effect sizes for adverse events and withdrawal rates were reported as relative risks (RR) and 95% confidence intervals (CI) using RevMan software. Forest plots were generated to visualise effect sizes for each comparison.

Results

Twenty-six eligible randomised controlled clinical trials (RCTs) were included in the pooled analysis (1 851 subjects). Finally, 14 and 13 adverse events were reported for the intervention and comparator groups, respectively, without any significant difference (RR: 0.99 [95% CI: 0.48, 2.05]; Z: 0.01, P: 0.99). Most adverse events in the experimental groups were mild gastrointestinal events. The intervention groups reported lower withdrawal rate than the comparator groups. However, the difference was not significant (RR: 0.81 [95% CI: 0.62, 1.05]; Z: 1.61, P: 0.11). These findings were consistent across Pistacia spp. and treatment indication subgroups.

Conclusion

The safety of Pistacia spp. was comparable to that of placebo, regular diet, or conventional treatments, with few adverse events and no serious adverse events. However, given the high risk of bias, such as small sample sizes, future high-quality, large-scale RCTs with diverse demographics are necessary to confirm the safety and efficacy of these preparations especially for specific populations or long-term usage.

{"title":"Adverse effects of herbal preparations of Pistacia species: a systematic review and meta-analysis of randomised controlled clinical trials","authors":"Saeid Mohseni , Narjes Gorji , Reihaneh Moeini , Zahra Meamariani , Hoda Shirafkan","doi":"10.1016/j.hermed.2024.100988","DOIUrl":"10.1016/j.hermed.2024.100988","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Pistacia</em> species (spp.) have nutritional and therapeutic usage. This systematic review and meta-analysis aimed to assess the safety of herbal preparations of <em>Pistacia</em> spp. in the randomised controlled clinical trials.</div></div><div><h3>Methods</h3><div>Relevant keywords were searched in PubMed, Embase, Scopus, Web of Science, and Google Scholar up to August 2023. The quality and risk of bias were assessed using the Cochrane Collaboration tool. Pooled effect sizes for adverse events and withdrawal rates were reported as relative risks (RR) and 95% confidence intervals (CI) using RevMan software. Forest plots were generated to visualise effect sizes for each comparison.</div></div><div><h3>Results</h3><div>Twenty-six eligible randomised controlled clinical trials (RCTs) were included in the pooled analysis (1851 subjects). Finally, 14 and 13 adverse events were reported for the intervention and comparator groups, respectively, without any significant difference (RR: 0.99 [95% CI: 0.48, 2.05]; Z: 0.01, <em>P</em>: 0.99). Most adverse events in the experimental groups were mild gastrointestinal events. The intervention groups reported lower withdrawal rate than the comparator groups. However, the difference was not significant (RR: 0.81 [95% CI: 0.62, 1.05]; Z: 1.61, <em>P</em>: 0.11). These findings were consistent across <em>Pistacia</em> spp. and treatment indication subgroups.</div></div><div><h3>Conclusion</h3><div>The safety of <em>Pistacia</em> spp. was comparable to that of placebo, regular diet, or conventional treatments, with few adverse events and no serious adverse events. However, given the high risk of bias, such as small sample sizes, future high-quality, large-scale RCTs with diverse demographics are necessary to confirm the safety and efficacy of these preparations especially for specific populations or long-term usage.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"49 ","pages":"Article 100988"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of antibacterial, antioxidant, cytotoxic properties and chemical composition of Oenanthe javanica (Blume) DC. essential oil

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-02-01 DOI: 10.1016/j.hermed.2024.100982

Rajneesh Kumar, Pooja Singh

Introduction

Bacterial food-borne diseases have been a major public health issue worldwide for decades. Oenanthe javanica (Blume) DC. is a small perennial herb of family Apiaceae, commonly found in Asia. The present study aims to evaluate the antibacterial, antioxidant, and cytotoxic capabilities, as well as the antibacterial mechanism of action, of Oenanthe javanica essential oil (OJEO).

Methods

In-vitro antibacterial activity was evaluated by Disc diffusion and microbroth dilution methods against Salmonella enterica serovar Typhimurium (ATCC 14028). Flow cytometric analysis was done to assess the effects of oil on membrane integrity and membrane potential. Electron Microscopy (SEM and TEM) was done to investigate morphological and intracellular damages initiated by the oil. Phytochemical profiling of oil was done by Gas Chromatography Mass - Spectrometry (GC-MS). Anti-proliferative property of OJEO was measured against 5 proliferative cell lines by MTT and NRU assay.

Results

OJEO exhibited encouraging antibacterial activity against Salmonella enterica serovar Typhimurium (ATCC 14028); MIC and MBC values were 1000 μg/mL and 1500 μg/mL, respectively. Oil treatment compromised bacterial membrane integrity and led to a decreased bacterial membrane potential. (SEM) and (TEM) analyses confirmed oil induced morphological and intracellular damage. Phytochemical characterization affirmed 47 components with β-pinene (11.29 %), γ-terpinene (32.55%), p-cymene (20.83%), α-terpinolene (7.42 %), myrcene (2.09 %) as major chemical constituents. Oil had moderate antiproliferative activity against A549, MCF-7, HaCat, HCT116 and HepG2 cell lines.

Conclusion

This study illustrates the significant antimicrobial, antioxidant, and cytotoxic properties of OJEO, indicating its potential as a therapeutic agent for bacterial diseases. Food systems and associated industries may utilise OJEO as a natural solution for combating food-borne bacteria and as a preservative agent.

{"title":"Assessment of antibacterial, antioxidant, cytotoxic properties and chemical composition of Oenanthe javanica (Blume) DC. essential oil","authors":"Rajneesh Kumar, Pooja Singh","doi":"10.1016/j.hermed.2024.100982","DOIUrl":"10.1016/j.hermed.2024.100982","url":null,"abstract":"<div><h3>Introduction</h3><div>Bacterial food-borne diseases have been a major public health issue worldwide for decades. <em>Oenanthe javanica</em> (Blume) DC. is a small perennial herb of family Apiaceae, commonly found in Asia. The present study aims to evaluate the antibacterial, antioxidant, and cytotoxic capabilities, as well as the antibacterial mechanism of action, of <em>Oenanthe javanica</em> essential oil (OJEO).</div></div><div><h3>Methods</h3><div>In-vitro antibacterial activity was evaluated by Disc diffusion and microbroth dilution methods against <em>Salmonella enterica</em> serovar Typhimurium (ATCC 14028). Flow cytometric analysis was done to assess the effects of oil on membrane integrity and membrane potential. Electron Microscopy (SEM and TEM) was done to investigate morphological and intracellular damages initiated by the oil. Phytochemical profiling of oil was done by Gas Chromatography Mass - Spectrometry (GC-MS). Anti-proliferative property of OJEO was measured against 5 proliferative cell lines by MTT and NRU assay.</div></div><div><h3>Results</h3><div>OJEO exhibited encouraging antibacterial activity against <em>Salmonella enterica</em> serovar Typhimurium (ATCC 14028); MIC and MBC values were 1000 μg/mL and 1500 μg/mL, respectively. Oil treatment compromised bacterial membrane integrity and led to a decreased bacterial membrane potential. (SEM) and (TEM) analyses confirmed oil induced morphological and intracellular damage. Phytochemical characterization affirmed 47 components with <em>β</em>-pinene (11.29 %), <em>γ</em>-terpinene (32.55%), <em>p</em>-cymene (20.83%), <em>α</em>-terpinolene (7.42 %), myrcene (2.09 %) as major chemical constituents. Oil had moderate antiproliferative activity against A549, MCF-7, HaCat, HCT116 and HepG2 cell lines.</div></div><div><h3>Conclusion</h3><div>This study illustrates the significant antimicrobial, antioxidant, and cytotoxic properties of OJEO, indicating its potential as a therapeutic agent for bacterial diseases. Food systems and associated industries may utilise OJEO as a natural solution for combating food-borne bacteria and as a preservative agent.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"49 ","pages":"Article 100982"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Bunium persicum and Piper nigrum in the Treatment of Patients With Alzheimer’s Disease: A Double-Blinded Randomised Clinical Trial

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-02-01 DOI: 10.1016/j.hermed.2024.100975

Arezoo Rajaee , Peyman Petramfar , Ramin Ansari , Sara Asadi , Afsaneh Vazin , Mohammad Mehdi Zarshenas

Introduction

Alzheimer's disease (AD), a common form of dementia, is a rapidly growing disease worldwide with a high financial burden that leads to morbidity and mortality. Current medications focus on symptom therapy and preventing disease progression. No curative management has been established for the disease till now. Persian medicine (PM) suggests various natural medications for what we know as AD in today's medicine. The goal of the present study is to assess the efficacy and safety of a memory enhancer formulation from PM.

Methods

A formulation from PM containing Bunium persicum (Boiss.) B.Fedtsch. and Piper nigrum L. (1:1) was selected and evaluated using a fixed dose (1 g/d) in patients with mild to moderate AD for 6 months in a double-blinded randomised clinical trial.

Results

Among 63 patients who completed the study, the drug group (33 patients) showed remarkable improvement (P-value < 0.001) in Persian clinical dementia rating scores, including memory, orientation, judgement/problem-solving, and home and hobbies domains. Moreover, medication has also reduced aggression, restlessness, insomnia, and impaired concentration during the study interval in the drug group. No adverse reaction was reported during the study interval.

Conclusions

This simple natural formulation can be considered a traditional-based product and used as a memory enhancer supplement in AD.

{"title":"Effects of Bunium persicum and Piper nigrum in the Treatment of Patients With Alzheimer’s Disease: A Double-Blinded Randomised Clinical Trial","authors":"Arezoo Rajaee , Peyman Petramfar , Ramin Ansari , Sara Asadi , Afsaneh Vazin , Mohammad Mehdi Zarshenas","doi":"10.1016/j.hermed.2024.100975","DOIUrl":"10.1016/j.hermed.2024.100975","url":null,"abstract":"<div><h3>Introduction</h3><div>Alzheimer's disease (<strong>AD</strong>), a common form of dementia, is a rapidly growing disease worldwide with a high financial burden that leads to morbidity and mortality. Current medications focus on symptom therapy and preventing disease progression. No curative management has been established for the disease till now. Persian medicine (<strong>PM</strong>) suggests various natural medications for what we know as AD in today's medicine. The goal of the present study is to assess the efficacy and safety of a memory enhancer formulation from PM.</div></div><div><h3>Methods</h3><div>A formulation from PM containing <em>Bunium persicum</em> (Boiss.) B.Fedtsch. and <em>Piper nigrum</em> L. (1:1) was selected and evaluated using a fixed dose (1 g/d) in patients with mild to moderate AD for 6 months in a double-blinded randomised clinical trial.</div></div><div><h3>Results</h3><div>Among 63 patients who completed the study, the drug group (33 patients) showed remarkable improvement (<em>P</em>-value < 0.001) in Persian clinical dementia rating scores, including memory, orientation, judgement/problem-solving, and home and hobbies domains. Moreover, medication has also reduced aggression, restlessness, insomnia, and impaired concentration during the study interval in the drug group. No adverse reaction was reported during the study interval.</div></div><div><h3>Conclusions</h3><div>This simple natural formulation can be considered a traditional-based product and used as a memory enhancer supplement in AD.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"49 ","pages":"Article 100975"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness and Safety of Blending Traditional Chinese Medicine With Western Medicine for Enhanced Secondary Stroke Prevention: A Meta-analysis of RCTs

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-02-01 DOI: 10.1016/j.hermed.2024.100953

C.L. Wen , L.-J. Song , C.-G. Ma , Z.-X. Su , F.-Y. Hu , L.-Q. Zhu

Introduction

To conduct a comprehensive evaluation of the efficacy and safety of combining traditional Chinese medication (TCM) with Western medication to improve secondary stroke prevention. Through meticulous analysis, we investigate the combined approach's potential to yield superior outcomes compared to stand-alone Western medical treatments.

Methods

We rigorously searched for RCTs on secondary stroke prevention using TCM and Western medicine (WM) from database creation to October 2023. PubMed, EMBASE, Cochrane Library, CNKI, SinoMed, WanFang, and VIP yielded pertinent studies. Stata 16.0 was used for comprehensive meta-analyses with predetermined inclusion and exclusion criteria.

Results

This thorough review comprised 40 randomised controlled trials with 3 478 treatment and 3 396 control participants. Combining TCM and WM significantly enhances secondary stroke prevention rates compared to WM alone (OR = 0.83, 95% CI: 0.55–1.12, P < 0.001). Compared to Western medical treatment for secondary stroke prevention, the integrated strategy significantly lowered the National Institutes of Health Stroke Scale score (OR = -0.62, 95% CI: -0.89, -0.35, P < 0.001). Furthermore, this integrated strategy effectively reduced stroke recurrence rates compared to Western medical therapy alone (OR = -0.94, 95% CI: -1.10, -0.76, P < 0.001). The rate of adverse reactions was not significantly different between Western medical treatment and integrated TCM (OR = 0.01, 95% CI: −0.18, 0.05, P = 0.131).

Conclusions

The evidence shows that combining TCM and Western therapy improves secondary stroke prevention. Besides improving clinical effectiveness, this integrated approach may reduce stroke recurrence. These findings strongly support the widespread use of this integrated approach in clinical practice.

{"title":"Effectiveness and Safety of Blending Traditional Chinese Medicine With Western Medicine for Enhanced Secondary Stroke Prevention: A Meta-analysis of RCTs","authors":"C.L. Wen , L.-J. Song , C.-G. Ma , Z.-X. Su , F.-Y. Hu , L.-Q. Zhu","doi":"10.1016/j.hermed.2024.100953","DOIUrl":"10.1016/j.hermed.2024.100953","url":null,"abstract":"<div><h3>Introduction</h3><div>To conduct a comprehensive evaluation of the efficacy and safety of combining traditional Chinese medication (TCM) with Western medication to improve secondary stroke prevention. Through meticulous analysis, we investigate the combined approach's potential to yield superior outcomes compared to stand-alone Western medical treatments.</div></div><div><h3>Methods</h3><div>We rigorously searched for RCTs on secondary stroke prevention using TCM and Western medicine (WM) from database creation to October 2023. PubMed, EMBASE, Cochrane Library, CNKI, SinoMed, WanFang, and VIP yielded pertinent studies. Stata 16.0 was used for comprehensive meta-analyses with predetermined inclusion and exclusion criteria.</div></div><div><h3>Results</h3><div>This thorough review comprised 40 randomised controlled trials with 3 478 treatment and 3 396 control participants. Combining TCM and WM significantly enhances secondary stroke prevention rates compared to WM alone (OR = 0.83, 95% CI: 0.55–1.12, <em>P</em> < 0.001). Compared to Western medical treatment for secondary stroke prevention, the integrated strategy significantly lowered the National Institutes of Health Stroke Scale score (OR = -0.62, 95% CI: -0.89, -0.35, <em>P</em> < 0.001). Furthermore, this integrated strategy effectively reduced stroke recurrence rates compared to Western medical therapy alone (OR = -0.94, 95% CI: -1.10, -0.76, <em>P</em> < 0.001). The rate of adverse reactions was not significantly different between Western medical treatment and integrated TCM (OR = 0.01, 95% CI: −0.18, 0.05, <em>P</em> = 0.131).</div></div><div><h3>Conclusions</h3><div>The evidence shows that combining TCM and Western therapy improves secondary stroke prevention. Besides improving clinical effectiveness, this integrated approach may reduce stroke recurrence. These findings strongly support the widespread use of this integrated approach in clinical practice.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"49 ","pages":"Article 100953"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Products in Leukaemia Research: A Bibliometric Review

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-01-31 DOI: 10.1016/j.hermed.2025.100993

Siddig Ibrahim Abdelwahab , Manal Mohamed Elhassan Taha , Syam Mohan

Introduction

This study evaluated the available literature concerning the diverse aspects of natural product activity against leukaemia.

Methods

Bibliometric data were obtained from the Scopus bibliographic database through search phrases developed from the MeSH database. Statistical analysis of the data was performed via Bibliometerix and VOSviewer. The search query was constructed on the basis of MeSH terms (D010936, D064209, and D007938) for the major topics. The data were further examined via bibliometric software tools such as Bibliometerix and VOSviewer.

Results

This bibliometric assessment covered original scientific articles from 1961 to 2023 in 1 039 journals and 4 704 documents with positive trends, which suggested a polynomial regression fit of the data (R² = 0.9346). The most active researcher is T. Efferth (Germany). The most advanced, cited, and collaborative nation is the United States. The key themes identified include ‘apoptosis,’ ‘cancer,’ ‘cytotoxicity,’ ‘HL-60 cells,’ and ‘Bcl-2.’ Thematic evolution reveals a shift toward emerging areas such as ‘molecular docking’ and ‘network pharmacology.’

Conclusions

These findings provide critical insights into research trends and highlight the evolving focus within leukaemia-related natural product studies, offering directions for future advancements.

{"title":"Natural Products in Leukaemia Research: A Bibliometric Review","authors":"Siddig Ibrahim Abdelwahab , Manal Mohamed Elhassan Taha , Syam Mohan","doi":"10.1016/j.hermed.2025.100993","DOIUrl":"10.1016/j.hermed.2025.100993","url":null,"abstract":"<div><h3>Introduction</h3><div>This study evaluated the available literature concerning the diverse aspects of natural product activity against leukaemia.</div></div><div><h3>Methods</h3><div>Bibliometric data were obtained from the Scopus bibliographic database through search phrases developed from the MeSH database. Statistical analysis of the data was performed via Bibliometerix and VOSviewer. The search query was constructed on the basis of MeSH terms (D010936, D064209, and D007938) for the major topics. The data were further examined via bibliometric software tools such as Bibliometerix and VOSviewer.</div></div><div><h3>Results</h3><div>This bibliometric assessment covered original scientific articles from 1961 to 2023 in 1 039 journals and 4 704 documents with positive trends, which suggested a polynomial regression fit of the data (R² = 0.9346). The most active researcher is T. Efferth (Germany). The most advanced, cited, and collaborative nation is the United States. The key themes identified include ‘apoptosis,’ ‘cancer,’ ‘cytotoxicity,’ ‘HL-60 cells,’ and ‘Bcl-2.’ Thematic evolution reveals a shift toward emerging areas such as ‘molecular docking’ and ‘network pharmacology.’</div></div><div><h3>Conclusions</h3><div>These findings provide critical insights into research trends and highlight the evolving focus within leukaemia-related natural product studies, offering directions for future advancements.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100993"},"PeriodicalIF":2.2,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the Therapeutic Efficacy of Habb-e-Ghafis in Non-alcoholic Fatty Liver Disease, a Randomised, Single-Blind, Standard-Controlled Trial

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-01-06 DOI: 10.1016/j.hermed.2024.100986

Nida Mehraj, Zaffar Hussain, Atiba Jan, Zarfah Fida

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder. Its emergence as a major health challenge has prompted a re-evaluation of therapeutic approaches, particularly considering the limitations associated with prevailing conventional treatments. It was hypothesized that Habb-e-Ghafis may exhibit therapeutic properties capable of ameliorating the pathological processes associated with NAFLD. The aim of the study was to evaluate the safety and efficacy of Habb-e-Ghafis in the treatment of non-alcoholic fatty liver disease.

Methods

This was a single-blind, randomised, standard-controlled clinical study. The study involved 44 non-alcoholic fatty liver disease patients, with 42 completing the trial. The study was approved by the Institutional Ethics Committee (IEC No.: RRIUMSGR/ MD-2019/CT/HG/NAFLD) on November 26, 2021, and registered with the Clinical Trials Registry-India (CTRI/2022/01/039497) on January 17, 2022. Patient recruitment commenced in March 2022 at RRIUM Hospital. The test group (22 patients) received Habb-e-Ghafis (3 pills, thrice daily) for 45 days, while the control group (22 patients) received Vitamin E (400 mg twice daily).

Results

Our study revealed the remarkable effectiveness of Habb-e-Ghafis in alleviating subjective symptoms. It significantly reduced liver span as quantified by Ultrasonography when compared to the standard medication. Concerning lipid profiles, the experimental drug notably reduced triglycerides and very low-density lipoprotein levels in comparison to the standard drug. Other lipid parameters showed similar effects in both treatment groups.

Conclusions

The results of this study suggest that Habb-e-Ghafis is more effective than the standard drug Vitamin E at reducing both subjective and objective parameters.

{"title":"Evaluating the Therapeutic Efficacy of Habb-e-Ghafis in Non-alcoholic Fatty Liver Disease, a Randomised, Single-Blind, Standard-Controlled Trial","authors":"Nida Mehraj, Zaffar Hussain, Atiba Jan, Zarfah Fida","doi":"10.1016/j.hermed.2024.100986","DOIUrl":"10.1016/j.hermed.2024.100986","url":null,"abstract":"<div><h3>Introduction</h3><div>Non-alcoholic fatty liver disease (<strong>NAFLD</strong>) is a prevalent metabolic disorder. Its emergence as a major health challenge has prompted a re-evaluation of therapeutic approaches, particularly considering the limitations associated with prevailing conventional treatments. It was hypothesized that <em>Habb-e-Ghafis</em> may exhibit therapeutic properties capable of ameliorating the pathological processes associated with NAFLD. The aim of the study was to evaluate the safety and efficacy of <em>Habb-e-Ghafis</em> in the treatment of non-alcoholic fatty liver disease.</div></div><div><h3>Methods</h3><div>This was a single-blind, randomised, standard-controlled clinical study. The study involved 44 non-alcoholic fatty liver disease patients, with 42 completing the trial. The study was approved by the Institutional Ethics Committee (IEC No.: RRIUMSGR/ MD-2019/CT/HG/NAFLD) on November 26, 2021, and registered with the Clinical Trials Registry-India (CTRI/2022/01/039497) on January 17, 2022. Patient recruitment commenced in March 2022 at RRIUM Hospital. The test group (22 patients) received <em>Habb-e-Ghafis</em> (3 pills, thrice daily) for 45 days, while the control group (22 patients) received Vitamin E (400 mg twice daily).</div></div><div><h3>Results</h3><div>Our study revealed the remarkable effectiveness of <em>Habb-e-Ghafis</em> in alleviating subjective symptoms. It significantly reduced liver span as quantified by Ultrasonography when compared to the standard medication. Concerning lipid profiles, the experimental drug notably reduced triglycerides and very low-density lipoprotein levels in comparison to the standard drug. Other lipid parameters showed similar effects in both treatment groups.</div></div><div><h3>Conclusions</h3><div>The results of this study suggest that <em>Habb-e-Ghafis</em> is more effective than the standard drug Vitamin E at reducing both subjective and objective parameters.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100986"},"PeriodicalIF":2.2,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phytotherapy: A Systematic Review for the Treatment of Hypertension

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-01-06 DOI: 10.1016/j.hermed.2024.100985

Rebeca Lachovicz, Vera Ferro-Lebres, Juliana Almeida-de-Souza

Introduction

Approximately 10 million annual deaths may be associated with hypertension. Adverse effects and non-response to pharmacological treatment limit therapy to a significant proportion of patients; hence, treatment alternatives seem necessary. Our objective was to review data about the impact of herbal medicine on reducing blood pressure (BP) in prehypertensive and hypertensive patients.

Methods

A systematic review was conducted (PRISMA guidelines), using PUBMED, SCOPUS, and WEB OF SCIENCE databases, without time restriction. The inclusion criteria were randomised controlled trials and quasi-experimental studies in humans focusing antihypertensive effect of phytotherapeutics: Allium sativum, Apium graveolens, Nigella sativa, Panax ginseng, and Hibiscus sabdariffa on BP in adults with prehypertension or hypertension. The exclusion criteria were the usage of combined medicinal plants. Data about systolic and diastolic BP differences before and after phytotherapy were extracted manually and summarised. The risk of bias was assessed using the JBI tool.

Results

Forty-five studies were selected (15 A sativum, 4 A graveolens, 4 N sativa, 9 P ginseng, and 13 H sabdariffa). Antihypertensive effect was observed for A sativum systolic and diastolic BP (−18.1/−9 mmHg), A graveolens (−37.9/−15.4 mmHg), N sativa (−11.8/−8.8 mmHg), P ginseng (−17.4/−7.1 mmHg), and H sabdariffa (−61.4/−66.2 mmHg).

Discussion/Conclusions

Herbal medicines can reduce high BP levels in prehypertension and hypertension, when used alone or together with lifestyle changes or antihypertensive drugs. Results interpretation is crucial, given the studies quality variation and the discrepancies. More consistent clinical studies in humans are needed to accurately determine efficacy and safety in the treatment of hypertension.

{"title":"Phytotherapy: A Systematic Review for the Treatment of Hypertension","authors":"Rebeca Lachovicz, Vera Ferro-Lebres, Juliana Almeida-de-Souza","doi":"10.1016/j.hermed.2024.100985","DOIUrl":"10.1016/j.hermed.2024.100985","url":null,"abstract":"<div><h3>Introduction</h3><div>Approximately 10 million annual deaths may be associated with hypertension. Adverse effects and non-response to pharmacological treatment limit therapy to a significant proportion of patients; hence, treatment alternatives seem necessary. Our objective was to review data about the impact of herbal medicine on reducing blood pressure (<strong>BP</strong>) in prehypertensive and hypertensive patients.</div></div><div><h3>Methods</h3><div>A systematic review was conducted (PRISMA guidelines), using PUBMED, SCOPUS, and WEB OF SCIENCE databases, without time restriction. The inclusion criteria were randomised controlled trials and quasi-experimental studies in humans focusing antihypertensive effect of phytotherapeutics: <em>Allium sativum</em>, <em>Apium graveolens</em>, <em>Nigella sativa</em>, <em>Panax ginseng</em>, and <em>Hibiscus sabdariffa</em> on BP in adults with prehypertension or hypertension. The exclusion criteria were the usage of combined medicinal plants. Data about systolic and diastolic BP differences before and after phytotherapy were extracted manually and summarised. The risk of bias was assessed using the JBI tool.</div></div><div><h3>Results</h3><div>Forty-five studies were selected (15 <em>A sativum</em>, 4 <em>A graveolens</em>, 4 <em>N sativa</em>, 9 <em>P ginseng</em>, and 13 <em>H sabdariffa)</em>. Antihypertensive effect was observed for <em>A sativum</em> systolic and diastolic BP (−18.1/−9 mmHg), <em>A graveolens</em> (−37.9/−15.4 mmHg), <em>N sativa</em> (−11.8/−8.8 mmHg), <em>P ginseng</em> (−17.4/−7.1 mmHg), and <em>H sabdariffa</em> (−61.4/−66.2 mmHg).</div></div><div><h3>Discussion/Conclusions</h3><div>Herbal medicines can reduce high BP levels in prehypertension and hypertension, when used alone or together with lifestyle changes or antihypertensive drugs. Results interpretation is crucial, given the studies quality variation and the discrepancies. More consistent clinical studies in humans are needed to accurately determine efficacy and safety in the treatment of hypertension.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100985"},"PeriodicalIF":2.2,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In-vitro microbicidal activity of Ganoderma lucidum aqueous extract against selected pathogenic bacteria and yeast

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-01-05 DOI: 10.1016/j.hermed.2025.100990

MacDonald Idu , Susan Omo Okojie , Benjamin Ogunma Gabriel

Introduction

The potential antibacterial properties of aqueous extracts of Ganoderma lucidum, particularly its ability to combat pathogenic bacteria and fungi, have captivated the interest of both the scholarly and pharmaceutical sectors. This investigation was conducted to explore the antimicrobial efficacy of aqueous extracts of G. lucidum: Sample A (subjected to boiling for 1 hour) and Sample B (subjected to boiling for 3 hours) against pathogenic bacteria and yeast.

Method

Standard microbiological procedures were used to isolate, identify, and determine the antimicrobial properties of the extracts. A standard procedure was utilised to prepare the samples.

Results

As evidenced in the study, a notable disparity was observed in the impact of the Sample A extract on the test isolates, with the most pronounced effect noted on Staphylococcus spp at a concentration of 1 000 mg/ml (10.33 ± 0.88 mm). Conversely, no antimicrobial activity (0.00 ± 0.00 mm) was detected in any concentration against E. coli, Enterobacter spp, Bacillus spp, and Candida spp. Moreover, the findings pertaining to Sample B indicated that the most substantial effect was observed on Pseudomonas spp at 1 000 mg/ml (6.67 ± 0.33 mm). Conversely, no antimicrobial efficacy (0.00 ± 0.00 mm) was observed in all concentrations of the extract against Staphylococcus spp and Candida spp, while E. coli, Enterobacter spp, and Bacillus spp exhibited no activity at concentrations of 125 and 62.5 mg/ml.

Conclusion

These findings demonstrate the presence of bioactive substances with a wide range of antibacterial action in G. lucidum confirming assertions of the traditional herbalists that some bacterial diseases in people may be treated with Ganoderma species, hence the need for further study on compound isolation guided bio-assay.

{"title":"In-vitro microbicidal activity of Ganoderma lucidum aqueous extract against selected pathogenic bacteria and yeast","authors":"MacDonald Idu , Susan Omo Okojie , Benjamin Ogunma Gabriel","doi":"10.1016/j.hermed.2025.100990","DOIUrl":"10.1016/j.hermed.2025.100990","url":null,"abstract":"<div><h3>Introduction</h3><div>The potential antibacterial properties of aqueous extracts of <em>Ganoderma lucidum</em>, particularly its ability to combat pathogenic bacteria and fungi, have captivated the interest of both the scholarly and pharmaceutical sectors. This investigation was conducted to explore the antimicrobial efficacy of aqueous extracts of <em>G. lucidum</em>: Sample A (subjected to boiling for 1 hour) and Sample B (subjected to boiling for 3 hours) against pathogenic bacteria and yeast.</div></div><div><h3>Method</h3><div>Standard microbiological procedures were used to isolate, identify, and determine the antimicrobial properties of the extracts. A standard procedure was utilised to prepare the samples.</div></div><div><h3>Results</h3><div>As evidenced in the study, a notable disparity was observed in the impact of the Sample A extract on the test isolates, with the most pronounced effect noted on <em>Staphylococcus</em> spp at a concentration of 1000 mg/ml (10.33 ± 0.88 mm). Conversely, no antimicrobial activity (0.00 ± 0.00 mm) was detected in any concentration against <em>E. coli</em>, <em>Enterobacter</em> spp, <em>Bacillus</em> spp, and <em>Candida</em> spp. Moreover, the findings pertaining to Sample B indicated that the most substantial effect was observed on <em>Pseudomonas</em> spp at 1000 mg/ml (6.67 ± 0.33 mm). Conversely, no antimicrobial efficacy (0.00 ± 0.00 mm) was observed in all concentrations of the extract against <em>Staphylococcus</em> spp and <em>Candida</em> spp, while <em>E. coli, Enterobacter</em> spp, and <em>Bacillus</em> spp exhibited no activity at concentrations of 125 and 62.5 mg/ml.</div></div><div><h3>Conclusion</h3><div>These findings demonstrate the presence of bioactive substances with a wide range of antibacterial action in <em>G. lucidum</em> confirming assertions of the traditional herbalists that some bacterial diseases in people may be treated with <em>Ganoderma</em> species, hence the need for further study on compound isolation guided bio-assay.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100990"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioactivities, medicinal properties, and advanced extraction techniques of Tarragon (Artemisia dracunculus): a comprehensive review

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine

Pub Date : 2025-01-02 DOI: 10.1016/j.hermed.2024.100989

Syamand A. Qadir , Farhang H. Awlqadr , Miran H. Qadir , Sherzad R.A. Tobakari , Aryan M. Faraj , Sahar H. Hamarashid , Tablo H. Salih , Mohammed N. Saeed

Introduction

Throughout history, medicinal plants have been used as essential for humans treatment. The antibacterial applications of tarragon (Artemisia dracunculus) in phytotherapy will be covered in this review study. Despite the advancements in pharmaceuticals, herbal remedies continue to be vital, especially in areas where access to modern therapy is limited. In addition, the antibacterial qualities of Tarragon plant extracts and their innovative extraction techniques are described in this review article.

Methods

A thorough examination of the literature looked at the chemical composition, historical uses, and modern extraction techniques of tarragon (A. dracunculus). The extraction techniques, such as the in-syringe reversed dispersive liquid-liquid microextraction (IS-R-DLLME), ultrasound-assisted extraction (UAE), deep eutectic solvents (DES), and pressurised liquid extraction (PLE), and the methods of review analysis the antibacterial properties of tarragon (A. dracunculus) extracts against dangerous microbes.

Results

Both Gram-positive and Gram-negative bacteria can be effectively resistant by tarragon (A. dracunculus) essential oils and extracts. Also the primary bioactive components were limonene, methyl eugenol, and estragole. The yield and purity of bioactive components were enhanced by novel extraction techniques such as IS-R-DLLME and UAE. At minimum inhibitory concentrations (MIC). Therefore, the essential oils demonstrated strong antibacterial action against Escherichia coli and Staphylococcus aureus.

Discussion/Conclusions

The tarragon (A. dracunculus) plant may be regarded as a potent natural antibacterial agent, especially for antibiotic-resistant illnesses. By combining traditional botanical knowledge with contemporary extraction methods, new medicinal compounds can be created. This study highlighted the need to explore the synergistic effects of tarragon's bioactive components and improve extraction methods in order to optimise therapeutic advantages. Ultimately, tarragon (A. dracunculus) may help antibiotic resistance and microbial illnesses.

{"title":"Bioactivities, medicinal properties, and advanced extraction techniques of Tarragon (Artemisia dracunculus): a comprehensive review","authors":"Syamand A. Qadir , Farhang H. Awlqadr , Miran H. Qadir , Sherzad R.A. Tobakari , Aryan M. Faraj , Sahar H. Hamarashid , Tablo H. Salih , Mohammed N. Saeed","doi":"10.1016/j.hermed.2024.100989","DOIUrl":"10.1016/j.hermed.2024.100989","url":null,"abstract":"<div><h3>Introduction</h3><div>Throughout history, medicinal plants have been used as essential for humans treatment. The antibacterial applications of tarragon (<em>Artemisia dracunculus</em>) in phytotherapy will be covered in this review study. Despite the advancements in pharmaceuticals, herbal remedies continue to be vital, especially in areas where access to modern therapy is limited. In addition, the antibacterial qualities of Tarragon plant extracts and their innovative extraction techniques are described in this review article.</div></div><div><h3>Methods</h3><div>A thorough examination of the literature looked at the chemical composition, historical uses, and modern extraction techniques of tarragon (<em>A. dracunculus</em>). The extraction techniques, such as the in-syringe reversed dispersive liquid-liquid microextraction (IS-R-DLLME), ultrasound-assisted extraction (UAE), deep eutectic solvents (DES), and pressurised liquid extraction (PLE), and the methods of review analysis the antibacterial properties of tarragon (<em>A. dracunculus</em>) extracts against dangerous microbes.</div></div><div><h3>Results</h3><div>Both Gram-positive and Gram-negative bacteria can be effectively resistant by tarragon (<em>A. dracunculus</em>) essential oils and extracts. Also the primary bioactive components were limonene, methyl eugenol, and estragole. The yield and purity of bioactive components were enhanced by novel extraction techniques such as IS-R-DLLME and UAE. At minimum inhibitory concentrations (MIC). Therefore, the essential oils demonstrated strong antibacterial action against <em>Escherichia coli</em> and <em>Staphylococcus aureus.</em></div></div><div><h3>Discussion/Conclusions</h3><div>The tarragon (<em>A. dracunculus</em>) plant may be regarded as a potent natural antibacterial agent, especially for antibiotic-resistant illnesses. By combining traditional botanical knowledge with contemporary extraction methods, new medicinal compounds can be created. This study highlighted the need to explore the synergistic effects of tarragon's bioactive components and improve extraction methods in order to optimise therapeutic advantages. Ultimately, tarragon (<em>A. dracunculus</em>) may help antibiotic resistance and microbial illnesses.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100989"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0